RESUMEN
Resumen ANTECEDENTES: Según el reporte de Upper Gastrointestinal Bleeding de Gastroenterology Clinics of North America, en 2008 se registraron 863,000 admisiones hospitalarias por hemorragia gastrointestinal, con mortalidad reportada de 15 a 20%. En México la mortalidad por sangrado del tubo digestivo alto es de 8.5%, pero aumenta hasta 63% cuando coexiste con otras enfermedades. El lactato se ha validado para el pronóstico de mortalidad en distintas áreas. OBJETIVO: Determinar la utilidad del lactato como pronóstico de mortalidad en pacientes con sangrado del tubo digestivo alto. MATERIAL Y MÉTODO: Estudio de cohorte retrospectivo, ambilectivo, observacional, analítico y unicéntrico, en el que de 2015 a 2016 se midió el lactato de pacientes admitidos por sangrado del tubo digestivo alto al momento del ingreso a la sala de urgencias del Hospital General Xoco, Ciudad de México; posteriormente se correlacionó con el diagnóstico de egreso, se buscó correlación entre sangrado del tubo digestivo alto y egreso por defunción. Se evaluaron como objetivos secundarios la relación entre lactato y hemoderivados transfundidos. RESULTADOS: Se incluyeron 30 pacientes. La media de lactato en hombres fue de 5.33 ± 0.53 mmol/L y en mujeres fue de 1.2 ± 3.84 mmol/L con p < 0.01. El tiempo de hospitalización fue de 6.43 ± 5.13 días. El análisis de supervivencia tomó como referencia la media de lactato de 4.78; 29 pacientes egresaron por mejoría, mientras que un paciente falleció sin encontrar relación entre las concentraciones de lactato y defunción como diagnóstico de egreso; sin embargo, no encontramos relación estadísticamente significativa. CONCLUSIONES: Tras realizar el análisis de nuestra población no encontramos una relación estadísticamente significativa entre las concentraciones de lactato a 4.78 mmol/L y la mortalidad. Se buscó también asociación entre las concentraciones de lactato y las complicaciones durante el internamiento; sin embargo, esto tampoco tuvo relación significativa. A pesar de los resultados obtenidos, consideramos que es necesario replantear el estudio con un enfoque distinto ajustando las características de población y el tamaño de la misma con el fin de aportar datos definitivos respecto a este biomarcador.
Abstract BACKGROUND: According to Upper Gastrointestinal Bleeding of Gastroenterology Clinics of North America, in 2008 there were 863,000 hospital admissions for gastrointestinal bleeding, with reported mortality of 15-20%. In Mexico, mortality from upper digestive tract bleeding represents 8.5%, but increases up to 63% when it coexists with other diseases. Lactate has been validated for the prognosis of mortality in different areas. OBJECTIVE: To determine the usefulness of lactate as prognosis factor of mortality in upper digestive tract bleeding. MATERIAL AND METHOD: A retrospective, ambilective, observational, analytical and unicenter cohort study was done measuring lactate in patients admitted for upper digestive tract bleeding at admission to the emergency room of Hospital General Xoco, Mexico City, from 2015 to 2016 later it was correlated with the diagnosis of discharge, seeking a correlation between upper digestive tract bleeding and discharge due to death. Lactate ratio and blood products transfused were evaluated as secondary objectives. RESULTS: There were included 30 patients. The mean lactate in men was 5.33 ± 0.53 mmol/L and in women were 1.2 ± 3.84 mmol/L with a p < 0.01. The hospitalization time was 6.43 ± 5.13 days. The survival analysis was based on the mean lactate of 4.78; 29 patients graduated for improvement, while one patient died without finding a relation between lactate and death levels as a diagnosis of discharge; however, we did not find statistically significant relationship. CONCLUSION: After analyzing our population we did not find a statistically significant relation between lactate levels at 4.78 mmol/L and mortality. We also looked for an association between lactate levels and complications during hospitalization; however, this either had significant relation. Despite of the obtained results, it is necessary to reconsider the study with a different approach adjusting the population characteristics and its size in order to obtain definitive data about this biomarker.
RESUMEN
Resumen ANTECEDENTES: el delirio es un síndrome clínico transitorio y reversible, ocurre frecuentemente en el marco de un proceso de enfermedad aguda, se caracteriza por la alteración de la conciencia que se acompaña de un cambio en las funciones cognoscitivas, sobreviene a lo largo de un breve periodo, habitualmente horas o días, y tiende a fluctuar a lo largo del día. El delirio constituye un problema de salud pública importante, se considera predictor independiente de resultados clínicos negativos con incremento de la mortalidad, la estancia hospitalaria, el costo de la atención y el deterioro cognitivo a largo plazo. La evidencia disponible no apoya la administración de medicamentos para prevenir el delirio en el paciente con enfermedad aguda. OBJETIVO: comprobar la seguridad y eficacia de haloperidol para el tratamiento y profilaxis del delirio. MATERIAL Y MÉTODO: ensayo clínico controlado, prospectivo, transversal, comparativo, en el que se estudiaron pacientes hospitalizados en el servicio de Medicina Interna del Hospital General Xoco de la Secretaría de Salud de la Ciudad de México, se calculó la escala PREDELIRIC al ingreso de los pacientes; se incluyeron en el estudio los pacientes con riesgo alto de delirio (PREDELIRIC >50%). Los pacientes se distribuyeron al azar en dos grupos, en el grupo 1 se aplicaron medidas no farmacológicas de prevención de delirio más la administración de haloperidol profiláctico y el grupo 2 recibió medidas no farmacológicas de prevención de delirio más placebo. RESULTADOS: se incluyeron 84 pacientes, distribuidos en dos grupos, cada uno con 42 pacientes, de los que 33 (40%) eran hombres. El 42% padeció delirio, el tipo mixto fue el más común. La profilaxis con haloperidol no demostró disminuir la incidencia de delirio (54 vs 46%, p=0.51) en comparación con el grupo control. El haloperidol profiláctico no ofreció diferencias significativas comparado con placebo en retrasar el inicio del delirio (media de 6.3 vs 6.8 días, p=0.98), en los días de estancia hospitalaria (mediana 9.5 vs 12 días, p=0.56) o en la duración del delirio (media 3 vs 3.5 días, p=0.32); tampoco tuvo efecto en la mortalidad (20 vs 10%, p=0.21). No se informaron efectos secundarios con la administración de haloperidol. CONCLUSIONES: la administración de haloperidol para la prevención del delirio en pacientes con riesgo alto de padecerlo no demostró diferencia significativa en comparación con el placebo en disminuir la incidencia de delirio, en retrasar el inicio de los síntomas, en la reducción de su duración, en reducir los días de estancia hospitalaria ni en la mortalidad. De acuerdo con nuestros resultados, por el momento no es posible recomendar la administracion de haloperidol en la profilaxis de delirio en pacientes con riesgo alto de padecerlo.
Abstract BACKGROUND: Delirium is a clinical transitory and reversible syndrome, occurs frequently in a setting of an acute disease process, it is characterized by the disorder of the consciousness accompanied by a change in the cognitive functions, it occurs throughout a brief period, usually hours or days and tends to vary during the day. Delirium is an important public health problem and it is considered independent predictor of negative clinical results with increased mortality, hospital stay, attention cost and cognitive damage to long-term. The available evidence does not support the administration of drugs to prevent delirium in patients with acute disease. OBJECTIVE: To prove the safety and efficacy of haloperidol for the treatment and prophylaxis of delirium. MATERIAL AND METHOD: A clinical, controlled, prospective, cross-sectional, comparative study was done, in which patients hospitalized at Internal Medicine service of General Hospital Xoco, Mexico City, were included. Scale PREDELIRIC was calculated at the entering of patients, including in the study those with high risk of delirium (PRE-DELIRIC >50%). Patients were randomly distributed into two groups, in the group 1 non pharmacological measures of delirium prevention were applied plus the administration of prophylactic haloperidol and group 2 was given non pharmacological measures of delirium prevention plus placebo. RESULTS: There were included 84 patients, distributed into two groups, each one with 42 patients, from which 33 (40%) were male; 42% suffer delirium, mix type was the most common. Prophylaxis with haloperidol did not show to reduce the incidence of delirium (54% vs 46%, p=0.51) compared with control group. Prophylactic haloperidol did not show significant differences compared to placebo in delaying the beginning of delirium (mean of 6.3 days vs 6.8 days, p=0.98), in days of hospital stay (mean 9.5 vs 12 days, p=0.56), or in the lasting of delirium (mean 3 vs 3.5 days, p=0.32). Prophylaxis with haloperidol did not show either effect on mortality (20% vs 10%, p=0.21). There were not secondary effects with haloperidol. CONCLUSIONS: Haloperidol administration to prevent delirium in patients with high risk of having it did not show significant difference compared to placebo in reducing delirium incidence, delaying the starting of symptoms, in reducing their lasting, in reducing the hospital stay nor in reducing mortality. According to our results, by now it is not possible to recommend the administration of haloperidol in the prophylaxis of delirium in patients with high risk of having it.
RESUMEN
Resumen ANTECEDENTES: la prehipertensión es una condición que aumenta el riesgo de padecer hipertensión arterial. Las concentraciones séricas elevadas de ácido úrico se asocian con hipertensión arterial y dificultan su control. OBJETIVO: evaluar las concentraciones circulantes de ácido úrico en pacientes prehipertensos en comparación con las de sujetos normotensos e hipertensos. MATERIAL Y MÉTODO: estudio clínico transversal en el que de enero a junio de 2016 las concentraciones séricas de ácido úrico se determinaron por método enzimático en pacientes con prehipertensión (de acuerdo con los criterios del JNC VII), así como en sujetos normotensos y sujetos hipertensos. Los métodos estadísticos usados fueron ANOVA y prueba exacta de Fisher. RESULTADOS: se incluyeron 90 pacientes con prehipertensión, 90 sujetos normotensos y 90 sujetos hipertensos. Encontramos que el grupo de prehipertensos tuvo valores significativamente mayores de ácido úrico que los normotensos (6.24±1.5 mg/dL vs 5.4±1.2 mg/dL, p=0.000206), mientras que aunque los valores en hipertensos fueron superiores (6.7±2 mg/dL), no alcanzaron significación estadística con los prehipertensos (p=0.99). Encontramos asociación significativa entre hiperuricemia con prehipertensión (p=0.015 IC 95%; 1.18-3.99). CONCLUSIONES: los pacientes prehipertensos mostraron concentraciones de ácido úrico superiores a las de los normotensos y aunque los valores mencionados fueron menores que en los hipertensos, esto no fue significativo. La hiperuricemia puede contribuir, al menos en parte, a mayor progresión hacia hipertensión arterial observada en los prehipertensos.
Abstract BACKGROUND: Prehypertension increases the risk of hypertension, serum uric acid levels are also associated with increased risk of hypertension. Increased levels of resistin and/or decreased levels of adiponectin are associated with cardiovascular mortality and the development of hypertension. OBJECTIVE: To evaluate uric acid serum levels in normotensive, prehypertensive and hypertensive patients. MATERIAL AND METHOD: A clinical, cross-sectional study was made from January to June 2016 in which circulating levels of uric acid were measured (enzymatic method) in normotensive, prehypertensive and hypertensive patients. Statistical analysis was performed with ANOVA and Fisher test. RESULTS: Ninety normotensive, 90 prehypertensive and 90 hypertensive patients were included. Prehypertensive patients have significantly greater levels of uric acid than normotensive subjects (6.24±1.5 mg/dL vs 5.4±1.2 mg/dL, p=0.000206). We also observed that hypertensive patients had increased, although non-significantly, values of uric acid than prehypertensive subjects (6.7±2 mg/dL, p=0.99). We also found a significantly association between hyperuricemia and prehypertension (p=0.015 IC 95%; 1.18-3.99). CONCLUSIONS: Prehypertensive patients had greater levels of uric acid when compared with normotensive subjects, this may explain why prehypertensive patients shown increased risk for hypertension than normotensive patients.
RESUMEN
OBJECTIVE: This study aimed to evaluate the levels of the adipokines, resistin and adiponectin in normotensive and high normal blood pressure patients. METHODS: Circulating levels of the adipokines, resistin and adiponectin were measured by enzyme-linked immunosorbent assay (ELISA; R'D Systems, Minneapolis) in 20 high normal blood pressure patients and in 20 age-matched normotensive non-diabetic subjects. Statistical analysis was performed with analysis of variance (ANOVA). RESULTS: The control group showed non-significantly decreased levels of resistin when compared with patients with high normal blood pressure [systolic 130-139 mmHg; diastolic 85-89 mmHg] (12.25 vs 14.38 pg/mL, p = 0.40). There were significantly higher levels of adiponectin in the control group when compared with high normal blood pressure patients (11.3 vs 7.51 µg/mL, p = 0.028). CONCLUSIONS: High normal blood pressure patients have increased levels of resistin and lower values of adiponectin when compared with age-matched non-diabetic normotensive subjects. This may explain why those patients showed more progression to hypertension, atherosclerosis and cardiovascular risk than normotensive subjects.
RESUMEN
In this clinical trial, we assessed the effectiveness and safety of isosorbide dinitrate spray administered through the oral mucosa in 20 elderly patients (> 60 years old) with a hypertensive emergency (mean arterial pressure > 140 mmHg and target-organ damage). The patents were given a first dose of 1.25 mg of spray when they were admitted; a second dose was administered 15 min. later if the mean arterial pressure had not decreased by > 15%. An electrocardiogram (ECG) was done on every patient immediately prior and 30 min. after administering the medication. Three patients (15%) had a good response with one dose while 17 patients (85%) required a second dose. Thirty patients had a significant reduction in arterial blood pressure (193 +/- 91,123 +/- 5.4 to 154 + 7.1/92.5 + 6.2 mmHg p < 0.005) as well as of the mean arterial pressure (146.8 +/- B to 113 +/- 5 mmHg 23%, p < 0.005 > in a period of 30 min. No adverse effects, rebound hypertension nor severe hypotension were observed. These figures remained under control for 3 h. Both ECG, were normal. A reduction of 13.5% heart rate was obtained (p < 0.005). Our observations suggest that isosorbide dinitrate aerosol is an effective and safe alternative for the treatment of elderly patients with hypertensive emergencies.
Asunto(s)
Hipertensión/tratamiento farmacológico , Dinitrato de Isosorbide/administración & dosificación , Vasodilatadores/administración & dosificación , Factores de Edad , Anciano , Urgencias Médicas , Femenino , Humanos , Masculino , Nebulizadores y VaporizadoresRESUMEN
BACKGROUND: Isosorbide dinitrate in spray form is an effective and safe option for the treatment of hypertensive emergencies. The aim of this study was to evaluate whether isosorbide dinitrate spray is as effective and safe as treatment in tablet form for the management of hypertensive emergencies in the elderly. METHODS: Forty patients with hypertensive emergencies were randomly divided into two groups of 20 patients each. Group A received 1.25 mg isosorbide dinitrate aerosol upon arrival and a second dose 15 min later when mean systemic arterial pressure (MAP) reduction was <15% . Group B patients received a single 5 mg tablet of sublingual isosorbide dinitrate. RESULTS: Blood pressure in Group A patients decreased from 193 +/- 13/123 +/- 6.6 mmHg to 154 +/- 15/92.5 +/- 7.6 mmHg (p < 0.005), the reduction beginning 10 min after drug administration; no adverse effects were found. Two patients in Group B did not respond but for the other patients in this group blood pressure decreased from 197 +/- 10/121 +/- 7 to 154 +/- 11/90 +/- 4 mmHg, (p < 0.005), the reduction beginning 45 min after receiving the medication; 8 patients suffered headache. CONCLUSION: Our results indicate that isosorbide dinitrate aerosol is more effective than tablets for the treatment of elderly patients with hypertensive emergencies.
Asunto(s)
Antihipertensivos/administración & dosificación , Urgencias Médicas , Hipertensión/tratamiento farmacológico , Dinitrato de Isosorbide/administración & dosificación , Vasodilatadores/administración & dosificación , Aerosoles , Anciano , Anciano de 80 o más Años , Antihipertensivos/efectos adversos , Antihipertensivos/uso terapéutico , Femenino , Cefalea/inducido químicamente , Humanos , Dinitrato de Isosorbide/efectos adversos , Dinitrato de Isosorbide/uso terapéutico , Masculino , Seguridad , Comprimidos , Resultado del Tratamiento , Vasodilatadores/efectos adversos , Vasodilatadores/uso terapéuticoRESUMEN
In this study the authors assessed the effectiveness and safety of isosorbide dinitrate aerosol administered through the oral mucosa in 30 adult patients who presented with a hypertensive crisis (mean arterial pressure > 130 mm Hg and evidence of target organ damage). The patients were given a first dose of 1.25 mg of aerosol when they were admitted to the hospital; a second dose was administered 15 minutes later if the mean arterial pressure had not decreased by > 15%. An electrocardiogram (ECG) was obtained for every patient immediately prior to and 30 minutes after administration of the medication. Nine patients (30%) had a good response with one dose, whereas 21 patients (70%) required a second dose. All 30 patients had a significant reduction of the arterial blood pressure (187+/-13 / 121+/-6.6 to 153+/-15.3 / 92.3+/-7.6 mm Hg; p<0.005) as well as of the mean arterial pressure (136.6+/-8 to 109.5+/-7 mm Hg; p<0.005) in a period of 30 minutes. No adverse effects, rebound hypertension, or severe hypotension were observed. These figures remained under control for 6 hours. Two of the patients had angina pectoris at admission and their ECG showed subepicardial ischemia, both of which disappeared with the medication. A second ECG appeared normal. A reduction of 14% in heart rate was obtained (95+/-15 to 82+/-14 beats per minute; p<0.005). These observations suggest that isosorbide dinitrate aerosol is an effective and safe alternative for the treatment of patients with hypertensive crises.
Asunto(s)
Diuréticos Osmóticos/uso terapéutico , Hipertensión/tratamiento farmacológico , Isosorbida/uso terapéutico , Administración Oral , Adulto , Aerosoles , Anciano , Análisis de Varianza , Angina de Pecho/tratamiento farmacológico , Presión Sanguínea/efectos de los fármacos , Encefalopatías/tratamiento farmacológico , Trastornos Cerebrovasculares/tratamiento farmacológico , Diuréticos Osmóticos/administración & dosificación , Esquema de Medicación , Electrocardiografía , Femenino , Estudios de Seguimiento , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Hipertensión/fisiopatología , Isosorbida/administración & dosificación , Masculino , Persona de Mediana Edad , Mucosa Bucal , Isquemia Miocárdica/tratamiento farmacológico , Admisión del Paciente , Pericardio/patología , Seguridad , Factores de TiempoRESUMEN
In this assay, we evaluated the utility of isosorbide given by a sprayer in the management of hypertensive crisis of severe preeclampsia. 36 pregnant women with severe preeclampsia received fluid therapy and were randomly dividend in two groups of 18 patients each. Group A, received isosorbide in spray 1.25 mg when admitted and a second dose 10 minutes after if mean arterial blood pressure decreased less than 15%. and group B, in whom 4 g of magnesium sulphate was infused in one hour and then 1 g each hour for a maximum of five hours. In all patients blood pressure, proteinuria, fetal and maternal heart rate and Apgar score at minute and five minutes were obtained. In Group A 13 patients had a significative blood pressure reduction with one application and 5 needed a second one (p < 0.002). fetal (p < 0.005), and maternal (p < 0.005) heart rate also had a significative reduction. Whereas three patients in Group B did not respond and the rest had a poor blood pressure control (p > 0.05) with no changes in fetal and maternal heart rate. No patient developed eclampsia. When compared both groups, there were a significative difference for blood pressure (p < 0.005), fetal heart rate (p < 0.002), maternal heart rate (p < 0.05) and Apgar at minute (p < 0.01) in isosorbide's group. Our data suggest that isosorbide given by a sprayer is effective and safer in the management of the hypertensive crisis of severe preeclampsia.